Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Cocconcelli (Padova, Italy), D. Biondini (Padova, Italy), N. Bernardinello (Padova, Italy), S. Baraldo (Padova, Italy), S. Lococo (Padova, Italy), G. Andreotti (Padova, Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova, Italy), E. Balestro (Padova, Italy), P. Spagnolo (Padova, Italy). Association between MUC5B rs35705950 genotype and response to antifibrotic treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).. 735

Member's Comments

No comment yet.

Related content which might interest you: Association between leukocyte telomere length (LTL) and functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features Source: International Congress 2017 – Functional genomics knowledge in parenchymal and bronchial diseases Year: 2017 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Angiopoietin-2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 MUC5B promoter polymorphism is significantly associated with idiopathic interstitial pneumonia in German but not in Japanese patients Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Ca 19-9 serum levels in patients with end-stage Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Polymorphism of the genes of xenobiothics detoxification in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2004; 24: Suppl. 48, 536s Year: 2004 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016